Browse studies

Find your next paid study

57 recruiting studies matching your filters

A Phase 2 Open-label Study to Evaluate the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least One Treatment (VAY2EXPLORE)

The purpose of this study is to investigate the tolerability of ianalumab (9 mg/kg) with investigator's choice thrombopoietin receptor agonist (IC TPO-RA) in p…

Primary Immune Thrombocytopenia (ITP)Primary Evans Syndrome (ES)

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT07421167

Phase 3

A Randomized, Multi-Center, Double-Blind, Phase III Study Evaluating the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia

The ExCIT study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thro…

Patients With Chemotherapy-Induced Thrombocytopenia

Estimated

~$10 – $8,750

Jiangsu HengRui Medicine Co., Ltd.NCT07286032

Patients' Preferences for Primary Immune Thrombocytopenia Treatment

This study aims to evaluate treatment preferences of patients with Primary Immune Thrombocytopenia (ITP) in the United States (US) by conducting a preference e…

Primary Immune Thrombocytopenia

Estimated

~$10 – $1,050

Novartis PharmaceuticalsNCT07786077

Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia

Background: * Idiopathic CD4+ lymphocytopenia (ICL) is a condition in which there is a decreased level of CD4+ lymphocytes (a type of white blood cell), which…

Idiopathic CD4+ LymphocytopeniaCryptococcal MeningitisWarts

Estimated

~$10 – $675

National Institute of Allergy and Infectious Diseases (NIAID)NCT00867269

Investigation of the Natural Progression of Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance.

Background: Clonal Hematopoiesis of Indeterminate Potential (CHIP) is a change in a person s DNA that can increase a person s risk of developing blood cancers…

Clonal Hematopoiesis of Indeterminate PotentialClonal Cytopenia of Undetermined Significance

Estimated

~$10 – $675

National Heart, Lung, and Blood Institute (NHLBI)NCT04102423

Phase 2

Phase2 Trial of High Dose Intravenous Ascorbic Acid as an Adjunct to Salvage Chemotherapy in Relapsed/ Refractory Lymphoma, Patients With Clonal Cytopenia of Undetermined Significance, and Chronic Myelomonocytic Leukemia

This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does …

Clonal Cytopenia of Undetermined SignificanceHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma+5 more

Estimated

~$10 – $6,250

Mayo ClinicNCT03418038

Phase 2

Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Idiopathic CD4 lymphocytopenia (ICL) is a rare syndrome defined by consistently low CD4 T cell counts (\<300/mm\^3) without evidence of HIV infection or other …

Idiopathic CD4-PositiveT-Lymphocytopenia

Estimated

~$10 – $5,625

National Institute of Allergy and Infectious Diseases (NIAID)NCT02015013

Phase 3

Multicenter, Open-Label, Randomized Study of Nipocalimab or IVIG in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

The purpose of this study is to assess the efficacy and safety of nipocalimab in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FN…

Thrombocytopenia, Neonatal Alloimmune

Estimated

~$10 – $8,750

Janssen Research & Development, LLCNCT06533098

Phase 1

A Phase 1/2, Dose-finding Study Investigating the Safety and Efficacy of Pirtobrutinib in Adults With Immune Thrombocytopenia

The purpose of the phase 1 part of this study was to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the stud…

Immune Thrombocytopenia (ITP)

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT06721013

Phase 1

A Phase 1/2 Dose Evaluation Trial of the Safety and Preliminary Efficacy of Anti CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease

This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 or Zugocabtagene geleuce…

Warm Autoimmune Hemolytic Anemia (WAIHA)ITP - Immune ThrombocytopeniaWarm Autoimmune Hemolytic Anemia+1 more

Estimated

~$10 – $8,750

CRISPR Therapeutics AGNCT07549698

Phase 3

A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Adults With Previously Untreated Primary Immune Thrombocytopenia (ITP).

This Phase 3 study is designed to evaluate the efficacy and safety of romiplostim in combination with predniso(lo)ne compared with predniso(lo)ne alone in adul…

Primary Immune Thrombocytopenia

An Open-Label, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants With Immune Thrombocytopenia

The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new d…

Immune Thrombocytopenia (ITP)

Estimated

~$10 – $8,750

Nuvig Therapeutics, Inc.NCT07095127